A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
Authors
Starling, NVázquez-Mazón, F
Cunningham, D
Chau, I
Tabernero, J
Ramos, F
Iveson, T
Saunders, Mark P
Aranda, E
Countouriotis, A
Ruiz-Garcia, A
Wei, G
Tursi, J
Guillen-Ponce, C
Carrato, A
Affiliation
Department of Medicine, Royal Marsden Hospital, NHS Foundation Trust, London and Sutton, UK.Issue Date
2012-01
Metadata
Show full item recordAbstract
This study evaluated the maximum tolerated dose (MTD) of sunitinib, a multitargeted tyrosine kinase inhibitor, combined with FOLFIRI (irinotecan 180 mg/m2 given over 90 min i.v. and l-leucovorin 200 mg/m2 given over 120 min on day 1, followed by 5-FU 400 mg/m2 bolus and then 2400 mg/m2 infused over 46 h) in untreated metastatic colorectal cancer (mCRC).Citation
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. 2012, 23 (1):119-27 Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdr046PubMed ID
21447616Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdr046